Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
53 verified discoveries match your filters.
In the prospective, single-arm, phase 2 ROBOCOLO trial, robotic-assisted surgery for resectable right-sided colon cancer met its primary safety endpoint (postoperative complication rate within 30 days), supporting robotic surgery as…
Primary source cited
Last reviewed
In the randomized, double-blind, phase 3 LEAP-012 trial, adding lenvatinib and pembrolizumab to TACE significantly extended progression-free survival compared with TACE alone (14.6 months versus 10.0 months) in patients with…
Primary source cited
Last reviewed
A population-based analysis of national mortality data in England (2001-2024) found a substantial reduction in cervical cancer mortality among women aged 20-29 associated with high uptake of England's HPV vaccination…
Primary source cited
Last reviewed
In the randomized, open-label, phase 3 innovaTV 301 trial, tisotumab vedotin significantly extended both overall survival (11.5 months versus 9.5 months) and progression-free survival (4.2 months versus 2.9 months), compared…
Primary source cited
Last reviewed
In the randomized, phase 3 ASCENT-07 trial, sacituzumab govitecan did NOT improve progression-free survival compared with standard-of-care chemotherapy as a first chemotherapy option for hormone-receptor-positive, HER2-negative advanced breast cancer --…
Primary source cited
Last reviewed
In the single-arm, phase 2 FIREFLY-1 trial, tovorafenib produced an objective response (tumor shrinkage or resolution) in about 67% of children and young adults with relapsed or refractory, BRAF-altered pediatric…
Primary source cited
Last reviewed
The FDA granted 510(k) clearance -- a real FDA regulatory action for a diagnostic device, distinct from the drug-approval pathway most other records on this site describe -- to Ibex…
Primary source cited
Last reviewed
In the single-arm, open-label, phase 1/2 MonumenTAL-1 trial, talquetamab produced meaningful, durable responses in patients with heavily pretreated, relapsed or refractory multiple myeloma who had already exhausted the major available…
Primary source cited
Last reviewed
In the randomized, phase 3 CodeBreaK 300 trial, sotorasib plus panitumumab significantly extended progression-free survival (5.6 months vs 2.0 months, hazard ratio 0.48) and improved objective response rate (26% vs…
Primary source cited
Last reviewed
The NHS-Galleri trial's PRIMARY endpoint — a statistically significant reduction in COMBINED stage III and IV cancer diagnoses — was NOT met. Reported secondary findings were more favorable: stage IV…
Primary source cited
Last reviewed